October 7, 2015
Recommended Topic Related To:


"Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.

Glaucoma is a leading cause of blindness. But because vision damage often occurs gradually, mos"...


How Supplied


SIMBRINZA™ (brinzolamide/brimonidine tartrate) Ophthalmic Suspension 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


The recommended dose is one drop of SIMBRINZA™ in the affected eye(s) three times daily. Shake well before use. SIMBRINZA™ ophthalmic suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.


Dosage Forms And Strengths

Suspension containing 10 mg/mL brinzolamide and 2 mg/mL brimonidine tartrate.

SIMBRINZA™ (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is supplied in white low density polyethylene (LDPE) DROP-TAINER® bottles with a natural LDPE dispensing-tip and white polypropylene cap as follows:

8 mL in a 10 mL bottle NDC 0065-4147-27

Storage and Handling

Store SIMBRINZA™ at 2 - 25°C (36 - 77°F).

Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA. 1-800-757-9195. alcon.medinfo@alcon.com. Revised: 04/2013

Last reviewed on RxList: 5/3/2013
This monograph has been modified to include the generic and brand name in many instances.

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.